Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 | ||||||||||||||||||||
| By: PR Newswire Association LLC. - 16 Apr 2024 | Back to overview list |
|||||||||||||||||||
|
GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first nine months of the fiscal year ended March 31, 2024, before the U.S. market opens on Friday, April 19, 2024.
The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:
Upon dialing-in, participants should ask to be joined into the YS Biopharma Co., Ltd. call. The replay will be accessible through April 26, 2024 by dialing the following numbers:
A live and archived webcast of the conference call will also be available at the Company's investor relations website at https://investor.ysbiopharm.com/. About YS Biopharma YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit www.ysbiopharma.com. Investor Relations Contact Alyssa Li Robin Yang
SOURCE YS Biopharma Co., Ltd. 
|
||||||||||||||||||||
|
|
||||||||||||||||||||
 | Back to overview list | |||||||||||||||||||
View original content to download multimedia: